Advertisement

Aids und HIV-Infektion — internistische Therapie und Diagnostik

  • F.-D. Goebel
  • S. Schubert
Chapter
  • 13 Downloads

Zusammenfassung

In den letzten Jahren hat sich eine dramatische Verbesserung der Therapierbarkeit der HIV-Infektion ergeben. Bereits in der ersten kontrollierten Studie mit Zidovudin [16] ließ sich im Jahre 1987 bei Patienten im fortgeschrittenen Krankheitsstadium „AIDS-related complex‟ oder Aids nachweisen, daß der Einsatz einer antiretroviral wirksamen Substanz zu einer meßbaren Lebensverlängerung führt. Alle placebokontrollierten Studien an therapienaiven Patienten haben den Vorteil einer aktiven Behandlung zeigen können, so daß eine alleinige Placebobehandlung in Therapiestudien heute praktisch nicht mehr vertretbar ist. Die Prüfung einer neuen Substanz oder Medikamentenkombination hat daher gegen eine Standardtherapie zu erfolgen.

Literatur

  1. 1.
    Abrams DI, Goldman AI, Launer C et al. (1994) A comparative trial of didano-sine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 330: 657–662PubMedCrossRefGoogle Scholar
  2. 2.
    Anonymous (1993) Recommendations on prophylaxis and therapy for disseminated Mycobacteriumavium complex for adults and adolescents infected with human immunodeficiency virus. U.S. Public Health Service Task Force on prophylaxis and therapy for mycobacterium avium complex. MMWR Morb Mortal Wkly Rep 42: 14–20Google Scholar
  3. 3.
    Anonymous (1995) Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. The Oral Ganciclovir European and Australian Cooperative Study Group. AIDS 9: 471–477Google Scholar
  4. 4.
    Anonymous (1996) [Überlegungen zur medikamentösen Postexpositionsprophylaxe nach beruflicher HIV-Exposition].Epidemiol Bull 43: 291–295Google Scholar
  5. 5.
    Anonymous (1996) Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet 348: 283–291CrossRefGoogle Scholar
  6. 6.
    Anonymous (1996) Update: Provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep 45: 468–472Google Scholar
  7. 7.
    Beral V, Peterman T, Berkelman R, Jaffe H( 1991) AIDS-associated non-Hodgkin lymphoma. Lancet 337: 805–809PubMedCrossRefGoogle Scholar
  8. 8.
    Bozzette SA, Finkelstein DM, Spector SA et al. (1995) A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 332: 693–699PubMedCrossRefGoogle Scholar
  9. 9.
    Brun-Vezinet F (1996) HIV viral load changes in delta patients. 3rd Conference on Retroviruses and Opportunistic Infections, Washington/DC (Abstract)Google Scholar
  10. 10.
    Busillo CP, Lessnau KD, Sanjana V et al. (1992) Multidrug resistant mycobacterium tuberculosis in patients with human immunodeficiency virus infection. Chest 102: 797–801PubMedCrossRefGoogle Scholar
  11. 11.
    Cameron B, Heath-Chiozzi M, Kravcik S (1997) Prolongation of life and pre-ventionof AIDS in advanced HIV immunodeficiency with ritonavir. 3rd Conference on Retroviruses and Opportunistic Infections, Washington/DC (Abstract)Google Scholar
  12. 12.
    Carpenter CC, Fischl MA, Hammer SM et al. (1996) Antiretroviral therapy for HIV infectionin 1996.Recommendations of an international panel. International AIDS Society, USA. JAMA 276: 146–154PubMedCrossRefGoogle Scholar
  13. 13.
    Coffin JM (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267: 483–489PubMedCrossRefGoogle Scholar
  14. 14.
    Connor EM, Sperling RS, Gelber R et al. (1994) Reduction of maternal-infant-transmission of human immunodeficiency virus type 1 with zidovudine treat-ment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 331: 1173–1180PubMedCrossRefGoogle Scholar
  15. 15.
    Dube MP, Holtom PD, Larsen RA (1992) Tuberculous meningitis inpatients with and without human immunodeficiency virus infection. Am J Med 93: 520–524PubMedCrossRefGoogle Scholar
  16. 16.
    Fischl MA, Richman DD, Grieco MH et al. (1987) The efficacy of azidothymi-dine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 317: 185–191PubMedCrossRefGoogle Scholar
  17. 17.
    Fisher RI, Gaynor ER, Dahlberg S et al. (1993) Comparison of a standardregi-men (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328: 1002–1006PubMedCrossRefGoogle Scholar
  18. 18.
    Gachot B, Wolff M, Clair B, Regnier B (1990) Severe tuberculosis in patients with human immunodeficiency virus infection. Intensive Care Med 16: 491–493PubMedCrossRefGoogle Scholar
  19. 19.
    Gerberding JL (1994) Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: Final report from a longitudinal study. J Infect Dis 170: 1410–1417PubMedCrossRefGoogle Scholar
  20. 20.
    Gerberding JL (1996) Prophylaxis for occupational exposure to HIV. Ann Intern Med 125: 497–501PubMedGoogle Scholar
  21. 21.
    Hammer SM, Katzenstein DA, Hughes MD et al. (AIDS Clinical Trials Group Study 175 Study Team) (1996) A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 percubic millimeter. N Engl J Med 335: 1081–1090CrossRefGoogle Scholar
  22. 22.
    Havlir DV, Dube MP, Sattler FR et al. (1996) Prophylaxis against disseminated mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. The California Collaborative Treatment Group. N Engl J Med 335: 392–398PubMedCrossRefGoogle Scholar
  23. 23.
    Hill AR, Premkumar S, Brustein S et al. (1991) Disseminated tuberculosis in the acquired immunodeficiency syndrome era. Am Rev Respir Dis 144: 1164–1170PubMedCrossRefGoogle Scholar
  24. 24.
    Hirsch MS (1992) The treatment of cytomegalovirus in AIDS-more than meets the eye [editorial; comment]. N Engl J Med 326: 264–266PubMedCrossRefGoogle Scholar
  25. 25.
    Ho DD (1995) Time to hit HIV, early and hard [editorial; comment]. N Engl J Med 333: 450–451PubMedCrossRefGoogle Scholar
  26. 26.
    Ho DD (1997) Can HIV be eradicated from an infected person? 4th Conference on Retroviruses and Opportunistic Infections, Washington/DC (Abstract)Google Scholar
  27. 27.
    Inderlied CB, Kemper CA (1992) Disseminated mycobacterium avium complex infection. AIDS Clin Rev: 131–172Google Scholar
  28. 28.
    Inderlied CB, Kemper CA, Bermudez LE (1993) The mycobacterium avium complex. Clin Microbiol Rev 6: 266–310PubMedGoogle Scholar
  29. 29.
    Jacobson MA, Mills J (1988) Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann Intern Med 108: 585–594PubMedGoogle Scholar
  30. 30.
    Johnson MP, Coberly JS, Clermont HC et al. (1992) Tuberculin skin test reactivity among adults infected with human immunodeficiency virus. J Infect Dis 166: 194–198PubMedCrossRefGoogle Scholar
  31. 31.
    Kahn JO, Lagakos SW, Richman DD et al. (1992) A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NI AID AIDS Clinical Trials Group. N Engl J Med 327: 581–587PubMedCrossRefGoogle Scholar
  32. 32.
    Kelleher AD, Roggensack M, Emery S, Carr A, Cooper DA (1997) Effect of IL2 therapy on T-cell responses to mitogens, recall and HIV-specific antigens. 4th Conference on Retroviruses and Opportunistic Infections, Washington/DC (Abstract)Google Scholar
  33. 33.
    Kinloch de Loes S, Perrin L (1995) Therapeutic interventions in primary HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 10 (Suppl 1): S 69–76CrossRefGoogle Scholar
  34. 34.
    Kitchen VS, Skinner C, Ariyoshi K et al. (1995) Safety and activity of saquinavir in HIV infection. Lancet 345: 952–955PubMedCrossRefGoogle Scholar
  35. 35.
    Larder BA, Kohli A, Bloor S et al. (1996) Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2’, 3’-dideoxyinosineor AZT plus 2’, 3’-dideoxycytidine combination therapy. The protocol 34, 225-02 Collaborative Group. J Virol 70: 5922–5929PubMedGoogle Scholar
  36. 36.
    Markowitz M, Cao Y, Vesanen M et al. (1997) Recent HIV infection treated with AZT, 3TC, and a potent protease inhibitor. 4th Conference on Retroviruses and Opportunistic Infections, Washington/DC (Abstract)Google Scholar
  37. 37.
    Mascellino MT, Rossi F, Iegri F, Iona E (1994) Rapid detection of mycobacteria by combining a radiometric detection system with DNA probes. Micro-biologica 17: 249–253Google Scholar
  38. 38.
    Massari F, Conant M, Mellors JW et al. (1996) A Phase II open-label, randomized study of the triple combination of indinavir, zidovudine (ZDV) and didanosine (DDI) versus indinavir alone and zidovudine/didanosine in antiretro-viral naive patients. 3rd Conference on Retroviruses and Opportunistic Infections, Washington/DC (Abstract)Google Scholar
  39. 39.
    Mellors JW, Rinaldo CR Jr, Gupta P et al. (1996) Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272: 1167–1170PubMedCrossRefGoogle Scholar
  40. 40.
    Murray JF (1990) Cursed duet: HIV infection and tuberculosis. Respiration 57: 210–220PubMedCrossRefGoogle Scholar
  41. 41.
    Murray HW, Squires KE, Weiss W et al. (1995) Stavudine in patients with AIDS and AIDS-related complex: AIDS Clinical Trials Group 089. J Infect Dis 171 (Suppl 2): SI 23–30CrossRefGoogle Scholar
  42. 42.
    Pantaleo G, Graziosi C, Demarest JF et al. (1993) HIV infection is active and progressive in lymphoid tissue during the clinically latent stage ofdisease. Nature 362: 355–358PubMedCrossRefGoogle Scholar
  43. 43.
    Pierce M, Crampton S, Henry D et al. (1996) A randomized trial of clari-thromycin as prophylaxis against disseminated mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 335: 384–391PubMedCrossRefGoogle Scholar
  44. 44.
    Podzamczer D, Santin M, Jimenez J, Casanova A, Bolao F, Gudiol GR (1993) Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of pneumocystis carinii pneumonia in HIV-infec-ted patients. AIDS 7: 501–506PubMedCrossRefGoogle Scholar
  45. 45.
    Polis MA, Masur H (1995) Promising new treatments for cytomegalovirus reti-nitis. JAMA 273: 1457–1459PubMedCrossRefGoogle Scholar
  46. 46.
    Saag MS, Powderly WG, Cloud GA et al. (1992) Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 326: 83–89PubMedCrossRefGoogle Scholar
  47. 47.
    Schneider MM, Hoepelman AI, Eeftinck JK et al. (1992) A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection.The Dutch AIDS Treatment Group. N Engl J Med 327: 1836–1841PubMedCrossRefGoogle Scholar
  48. 48.
    Schuurman R, Nijhuis M, Leeuwen R van et al. (1995) Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC) J Infect Dis 171: 1411–1419PubMedGoogle Scholar
  49. 49.
    Shafran SD, Singer J, Zarowny DP et al. (1996) A comparison of two regimens for the treatment of mycobacterium avium complex bacteremia in AIDS: rifa-butin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimi-ne, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med 335: 377–383PubMedCrossRefGoogle Scholar
  50. 50.
    Small PM, Schecter GF, Goodman PC et al. (1991) Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 324: 289–294PubMedCrossRefGoogle Scholar
  51. 51.
    Staszewski S, Massari FE, Kober A et al. (1995) Combination therapy with zido-vudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697, 661, a nonnucleoside reverse tran-scriptase inhibitor. J Infect Dis 171: 1159–1165PubMedCrossRefGoogle Scholar
  52. 52.
    Theuer CP, Hopewell P., Elias D, Schecter GF, Rutherford GW, Chaisson. RE (1990) Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis 162:8–12PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • F.-D. Goebel
  • S. Schubert

There are no affiliations available

Personalised recommendations